V180 Dengue Vaccine Description
Merck & Co's adjuvanted, tetravalent subunit vaccine V180 comprises truncated forms of envelope proteins (DEN-80E), derived from strains of all four dengue virus serotypes (DEN-1 strain 258848, DEN-2 strain PR159 S1, DEN-3 strain CH53489, and DEN-4 strain H241). The DEN-80E subunits are expressed from plasmids in the Drosophila S2 cell expression system and are formulated with either ISCOMATRIX (saponin, cholesterol, and phospholipid adjuvant; CSL) or Alhydrogel (aluminum hydroxide gel adjuvant; Brenntag Nordic).
The V180 vaccine is indicated to prevent dengue fever.
The technology was originally developed at the National Institutes of Health.
V180 Dengue Vaccine Dosage
V180 is administered as an intramuscular injection.
V180's more compact dosing schedule could make it a more attractive alternative to Dengvaxia, particularly for travelers. However, its current three-dose schedule could still be improved to reduce the risk of non-compliance. It is believed that V180 would achieve its greatest commercial potential as part of a heterologous prime-boost strategy with TetraVax-DV (tetravalent live-attenuated chimeric vaccine; Biological E/Panacea Biotec/Butantan Institute/Merck & Co/Vabiotech), which the company has in-licensed from the US National Institutes of Health, potentially simplifying the vaccination schedule to just two doses.
V180 Dengue Vaccine News
February 15, 2018 - Global Drug Analysis: V180 - More Compact Dosing Schedule Could Make It a More Attractive Alternative to Dengvaxia.
V180 Dengue Vaccine Clinical Trials
Clinical Trial NCT02450838: Evaluating the Safety, Tolerability, and Immunogenicity of a Tetravalent Dengue Vaccine (V180) in Healthy Adults Who Previously Received a Live-Attenuated Tetravalent Vaccine (TV003 or TV005) - Last Update Posted: April 4, 2016.
- The purpose of this study is to evaluate the safety, tolerability, and immunogenicity of adjuvanted (with Alhydrogel™) and nonadjuvanted formulations of V180 in healthy adults who have previously received the live-attenuated tetravalent dengue vaccine TV003 or TV005.
- Participants will be randomly assigned to receive one intramuscular injection of either adjuvanted V180, nonadjuvanted V180, or placebo at study entry (Day 1).
- Participants will record their temperature and any adverse events for 14 days after receiving the vaccination. Additional study visits will occur on Days 15, 28, and 180.
- Visits will include a physical examination and blood and urine collection.
- Study staff will contact participants by telephone at Days 7 and 90 (and at other occasional time points between Days 90 and 180) for health and safety follow-up monitoring.
Clinical Trial NCT01477580: Study of a Dengue Vaccine (V180) in Healthy Adults (V180-001) (Completed, No results posted) - Last Update Posted: January 15, 2019.
- This study will determine whether at least one formulation of an experimental dengue vaccine (V180) is safe and causes an immune response.
- A Phase I Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Tetravalent Recombinant Subunit Dengue Vaccine (V180) in Healthy Adults.